|
|
You are subscribed to receive research study announcements from the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. To learn more about the study below, or other studies, please call us at 866-444-1132.
National Institutes of Health
Researching a more effective treatment to prevent relapse for severe aplastic anemia (SAA)
Aplastic anemia is a rare and serious blood disorder. Patients with severe aplastic anemia commonly receive cyclosporine to help improve blood counts. When cyclosporine treatment stops, the disease may return in one in three people.
Researchers at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland are studying if sirolimus, an immunosuppressant medication, can help prevent a relapse in patients diagnosed with severe aplastic anemia after stopping cyclosporine treatment.
What is involved?
Participants will:
- Be randomly assigned to two groups:
- one group will stop taking cyclosporine and receive sirolimus for 3 months;
- second group will stop taking cyclosporine and not receive any medication but will be closely monitored
- Receive a full medical history, physical examination, and bone marrow biopsy
- Be asked to participate for up to five years
- Received study related medication, tests, and procedures at no cost
To be eligible for this study, you must:
- Be 2 years or older
- Have responded to immunosuppressive therapy that includes cyclosporine and continue on cyclosporine.
|
|
|
The NIH Clinical Center, America’s Research Hospital located in Bethesda, MD
Metro red line (Medical Center stop)
For more information:
NIH Clinical Center Office of Patient Recruitment
866-444-1132
For those who are Deaf, Hard-of-Hearing, or Speech Impaired
800-877-8339
Se habla español
Email: PRPL@cc.nih.gov
Online:https://go.usa.gov/xnuz3
NIH Study: 17-H-0019
|
|
|
|
